In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic respons ...

The US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz), from US pharma major Eli Lilly, for the ...

The city of Meriden, Connecticut, filed a lawsuit in federal court on Monday, accusing 20 companies, including major drug manufacturers such as CVS Health Corp., Eli Lilly and Co., and Novo Nordisk ...

As the Biden presidency winds down, the administration touted its Cancer Moonshot accomplishments, including regulatory action against forever chemicals and ethylene oxide, expanded access to cancer ...

In a bid to bring down the cost of insulin, California under Gov. Gavin Newsom inked a contract to produce the drug. It's ...

USA News Group – How we deal with future spikes in disease cases and potential global pandemics is evolving rapidly. Not only is the World Economic Forum championing more ...

Eli Lilly stock undercut its 50-day line on Jan. 14 after cutting its fourth-quarter and 2024 outlook. Is LLY stock a sell ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Berenberg analyst Kerry Holford lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,050 and keeps a Buy rating on the shares.

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Eli Lilly (LLY) announced that the FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh ...